deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02930109

A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

Sponsor: Prescient Therapeutics, Ltd.

Conditions Acute Leukemia
Interventions Cytarabine PTX-200
Updated 13 times since 2017 Last updated: Apr 3, 2024 Started: Dec 9, 2016 Primary completion: Oct 31, 2023 Completion: Mar 4, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Leukemia and is currently completed. Prescient Therapeutics, Ltd. leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Apr 2019 · 7 months · monthly snapshot~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2023 · 24 months · monthly snapshot~Mar 2023 – ~May 2024 · 14 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown Status → Completed

  4. Mar 2023 — May 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  5. Mar 2021 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Apr 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  7. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Prescient Therapeutics, Ltd.
Data source: Prescient Therapeutics, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations